Business Standard

Monday, December 23, 2024 | 02:57 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

GSK sees sales growth in 2022 after quarterly beat, prepares for spin-off

The results underscore a comeback for GSK in the race to help fight the Covid-19 pandemic after it failed to bring a vaccine to the market so far

GlaxoSmithKline, gsk
Premium

GSK shares were up 0.2% at 0845 GMT

Reuters
Britain's GSK forecast growth in 2022 after racking up 1.4 billion pounds ($1.9 billion) in COVID-related sales in 2021, beating quarterly forecasts in its first earnings report since rejecting Unilever's bid for its consumer arm.

The results underscore a comeback for GSK in the race to help fight the COVID-19 pandemic after it failed to bring a vaccine to the market so far. The spin off of the consumer venture with Pfizer has also put the future in focus as boss Emma Walmsley faces pressure from activist investors.

"We have ended the year strongly, with another quarter of excellent performance

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in